Angiotech at buy by Merrill

Merrill Lynch analyst Hari Sambasivam gave Angiotech Pharmaceuticals Inc. a buy rating after Abbott's Xience stent elicited statistically significant superiority data in relation to in-stent late loss compared to Taxus in the Spirit II study. Superiority was unexpected, according to the analyst. Shares of the Vancouver, B.C.-based medical technology company were down 32 cents, or 2.69%, at $11.58. (Nasdaq: ANPI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.